<html><head></head><body><h1>Abciximab</h1><p class="drug-subtitle"><b>Class:</b> Platelet-aggregation Inhibitors<br/>
- Antithrombotic Agents<br/>
- Platelet-aggregation Inhibitors<br/>
- GP IIb/IIIa Receptor Inhibitors<br/>
<b>Chemical Name:</b> Human mouse monoclonal c7E3 clone p7E3VHhCgamma4 Fab fragment anti-human glycoprotein IIb/IIIa receptor immunoglobulin G disulfide with human-mouse monoclonal c7E3 clone p7E3vkhCk light chain<br/>
<b>CAS Number:</b> 143653-53-6<br/>
<b>Brands:</b> ReoPro</p><ul class="ddc-anchor-links"><li>Uses</li>
<li>Dosage</li>
<li>Cautions</li>
<li>Interactions</li>
<li>Pharmacokinetics</li>
<li>Patient advice</li>
<li>Preparations</li></ul><h2>Introduction</h2><p>Platelet aggregation inhibitor; a platelet glycoprotein (GP IIb/IIIa)-receptor inhibitor.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;5&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2 class="ddc-anchor-offset" id="uses">Uses for Abciximab</h2><h3>Acute Ischemic Complications of PCI</h3><p>Adjunct to anticoagulant therapy (e.g., heparin [referring throughout this monograph to unfractionated heparin], low molecular weight heparin), aspirin, and a P2Y12 platelet adenosine diphosphate (ADP)-receptor antagonist (e.g., clopidogrel, prasugrel, ticagrelor) to prevent acute cardiac ischemic complications in patients undergoing PCI or in patients with non-ST-segment-elevation acute coronary syndromes (NSTE ACS; unstable angina or non-ST-segment-elevation MI [NSTEMI]) not responding to conventional medical therapy in whom PCI is planned within 24 hours.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;5&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;7&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;10&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;11&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;91&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;994&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;995&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1100&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Adjunctive therapy with a GP IIb/IIIa-receptor inhibitor can reduce the incidence of cardiac ischemic events, including subsequent MI and death, in patients with NSTE ACS undergoing PCI and in patients without these conditions undergoing PCI.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;10&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;11&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;17&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;47&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;48&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;49&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;50&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;51&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Safety and efficacy in patients not undergoing PCI not established.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1016&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>The American College of Cardiology Foundation (ACCF), AHA, the Society for Cardiovascular Angiography and Interventions (SCAI), and other experts currently do not recommend <i>routine</i> use of GP IIb/IIIa-receptor inhibitors in patients with ST-segment elevation MI (STEMI) undergoing PCI; however, selective use of these drugs as an adjunct to heparin may be reasonable in certain high-risk patients (e.g., those with large anterior MI and/or large thrombus).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;994&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1016&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>ACCF/AHA/SCAI state that administration of a GP IIb/IIIa-receptor inhibitor at the time of PCI as an adjunct to heparin may be particularly useful in patients with NSTE ACS who have high-risk features (e.g., elevated troponin) and are not receiving bivalirudin and are not adequately pretreated with clopidogrel.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;994&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Regarding choice of GP IIb/IIIa-receptor inhibitor in patients undergoing PCI, IV abciximab, “double-bolus” IV eptifibatide, and high-dose tirofiban given by direct IV injection all produce a high degree of platelet inhibition and reduce ischemic complications.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;994&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Non-ST-Segment-Elevation Acute Coronary Syndromes</h3><p>Has been used in patients with unstable angina or NSTEMI (i.e., NSTE ACS) managed with conservative medical therapy only†; however, manufacturer and some clinicians state that safety and efficacy of abciximab not established in such patients who are <i>not</i> undergoing PCI.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;991&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>A GP IIb/IIIa-receptor inhibitor may be used in conjunction with aspirin prior to diagnostic angiography (“upstream”) in patients with NSTE ACS in whom an initial invasive management strategy is planned; however, IV eptifibatide or tirofiban is the preferred GP IIb/IIIa inhibitor for this use.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;991&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Abciximab is recommended in this situation only if there is no appreciable delay before angiography and PCI is likely to be performed.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;991&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2 class="ddc-anchor-offset" id="dosage">Abciximab Dosage and Administration</h2><h3>General</h3><ul>
<li>
<p>Discontinue infusion in patients in whom PCI has failed.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
</ul><p>Discontinue infusion in patients in whom PCI has failed.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><ul>
<li>
<p>Used in conjunction with aspirin and heparin in clinical studies.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Dosage of heparin required to maintain an appropriate activated clotting time (ACT) during concomitant therapy with abciximab may be lower than with heparin monotherapy.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;19&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;994&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Specific Drugs under Interactions.)</p>
</li>
</ul><p>Used in conjunction with aspirin and heparin in clinical studies.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Dosage of heparin required to maintain an appropriate activated clotting time (ACT) during concomitant therapy with abciximab may be lower than with heparin monotherapy.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;19&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;994&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Specific Drugs under Interactions.)</p><ul>
<li>
<p>Aspirin: In clinical studies, patients received 325 mg 2 hours prior to PCI and daily thereafter.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;77&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; ACCF/AHA/SCAI recommends that aspirin 325 mg be given prior to PCI in patients not already receiving maintenance aspirin therapy.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;994&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Patients already receiving maintenance aspirin therapy should receive a dose of 81–325 mg before the procedure.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;994&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>P2Y12-receptor antagonist: A loading dose of clopidogrel, prasugrel, or ticagrelor also is recommended prior to PCI in those undergoing stent placement.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;994&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Heparin sodium: In clinical studies, patients received 70 units/kg if baseline ACT &lt;150 seconds, 50 units/kg if baseline ACT was 150–199 seconds, or no heparin if baseline ACT ≥200 seconds; additional injections of 20 units/kg were given to maintain an ACT of ≥200 seconds during the procedure.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Experts suggest use of lower dosages of concomitant IV heparin sodium (e.g., 50–70 units/kg) given 6 hours prior to PCI and targeted to an ACT of ≥200 seconds.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;10&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;12&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;16&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;19&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;45&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;46&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;77&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;994&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Laboratory Monitoring under Cautions.) Postprocedural use of heparin generally not recommended.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;10&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;22&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;77&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
</ul><p>Aspirin: In clinical studies, patients received 325 mg 2 hours prior to PCI and daily thereafter.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;77&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; ACCF/AHA/SCAI recommends that aspirin 325 mg be given prior to PCI in patients not already receiving maintenance aspirin therapy.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;994&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Patients already receiving maintenance aspirin therapy should receive a dose of 81–325 mg before the procedure.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;994&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>P2Y12-receptor antagonist: A loading dose of clopidogrel, prasugrel, or ticagrelor also is recommended prior to PCI in those undergoing stent placement.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;994&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Heparin sodium: In clinical studies, patients received 70 units/kg if baseline ACT &lt;150 seconds, 50 units/kg if baseline ACT was 150–199 seconds, or no heparin if baseline ACT ≥200 seconds; additional injections of 20 units/kg were given to maintain an ACT of ≥200 seconds during the procedure.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Experts suggest use of lower dosages of concomitant IV heparin sodium (e.g., 50–70 units/kg) given 6 hours prior to PCI and targeted to an ACT of ≥200 seconds.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;10&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;12&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;16&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;19&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;45&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;46&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;77&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;994&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Laboratory Monitoring under Cautions.) Postprocedural use of heparin generally not recommended.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;10&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;22&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;77&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Administration</h3><p>For solution and drug compatibility information, see Compatibility under Stability.</p><p>Administer by IV injection followed by IV infusion using a controlled-infusion device (e.g., pump).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Do not shake vial.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Filter injection upon dilution, prior to IV administration, or during IV infusion using a sterile, nonpyrogenic, low-protein-binding filter (0.2 or 5 µm).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;7&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>For IV injection, withdraw appropriate dose into syringe and filter injection prior to administration.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Discard unused portion.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Do not admix or administer other drugs in the same IV line with abciximab injection or infusion.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>For IV infusion, withdraw appropriate dose into syringe and inject into an appropriate container of 0.9% sodium chloride or 5% dextrose injection.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>For IV injection, administer over at least 1 minute.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;7&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Dosage</h3><p>Patients undergoing PCI: 0.25 mg/kg by IV injection 10–60 minutes prior to PCI,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;7&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; followed by IV infusion of 0.125 mcg/kg per minute (maximum of 10 mcg/minute) for 12 hours.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Patients scheduled to receive PCI within 24 hours: 0.25 mg/kg by IV injection, followed by IV infusion of 10 mcg/minute for 18–24 hours, concluding 1 hour after procedure.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Prescribing Limits</h3><p>Patients undergoing PCI: Maximum 10 mcg/minute (as IV infusion) for 12 hours.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Special Populations</h3><p>No special population dosage recommendations at this time.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2 class="ddc-anchor-offset" id="cautions">Cautions for Abciximab</h2><h3>Contraindications</h3><ul>
<li>
<p>Bleeding diathesis, active internal bleeding, or recent (within 6 weeks) clinically important GI or genitourinary bleeding.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Severe uncontrolled hypertension.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Recent (within 6 weeks) major surgery or trauma.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>History of cerebrovascular accident (CVA) in preceding 2 years or CVA with serious substantial residual neurologic deficit.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Recent (within previous 7 days) oral anticoagulant therapy unless prothrombin time (PT) is ≤1.2 times control value.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Thrombocytopenia (platelet count &lt;100,000/mm<sup>3</sup>).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Intracranial neoplasm.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Arteriovenous malformation or aneurysm.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Use of IV dextran prior to or during PCI.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Presumed or documented history of vasculitis.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Known hypersensitivity to any ingredient in the formulation or to murine proteins.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;9&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
</ul><p>Bleeding diathesis, active internal bleeding, or recent (within 6 weeks) clinically important GI or genitourinary bleeding.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Severe uncontrolled hypertension.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Recent (within 6 weeks) major surgery or trauma.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>History of cerebrovascular accident (CVA) in preceding 2 years or CVA with serious substantial residual neurologic deficit.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Recent (within previous 7 days) oral anticoagulant therapy unless prothrombin time (PT) is ≤1.2 times control value.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Thrombocytopenia (platelet count &lt;100,000/mm<sup>3</sup>).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Intracranial neoplasm.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Arteriovenous malformation or aneurysm.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Use of IV dextran prior to or during PCI.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Presumed or documented history of vasculitis.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Known hypersensitivity to any ingredient in the formulation or to murine proteins.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;9&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Warnings/Precautions</h3><p>Risk of major bleeding (e.g., intracranial hemorrhage, genitourinary or GI bleeding, bleeding at arterial access site) and minor bleeding (e.g., spontaneous gross hematuria, spontaneous hematemesis); may require blood or platelet transfusions.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;5&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Bleeding Precautions and see Laboratory Monitoring under Cautions.)</p><p>Pulmonary alveolar hemorrhage reported rarely.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Increased risk of major bleeding observed in patients weighing ≤75 kg;&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;5&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; during concomitant thrombolytic therapy;&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; when PCI is performed within 12 hours of onset of symptoms of MI;&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; following prolonged (&gt;70 minutes) PCI;&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; or following failed PCI.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;9&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>If bleeding cannot be controlled by pressure, discontinue abciximab and concomitant heparin immediately.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Possible anaphylaxis.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; If anaphylaxis occurs, discontinue abciximab immediately and initiate appropriate treatment; drugs for treatment of hypersensitivity reactions (e.g., epinephrine, dopamine, theophylline, antihistamines, corticosteroids) should be immediately available.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Formation of human antichimeric antibody (HACA) reported.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;8&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;16&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;22&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;23&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;54&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;63&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;65&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Possible hypersensitivity reactions (including anaphylaxis), thrombocytopenia, or diminished antithrombotic effect if abciximab is readministered or if monoclonal antibodies are administered in patients with HACA titers.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>To reduce risk of bleeding, adhere to strict anticoagulation guidelines; use a short course of low-dose, weight-adjusted heparin; avoid vascular and other trauma; carefully manage vascular (e.g., femoral artery) access site; and monitor all potential bleeding sites during and following treatment.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;44&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;60&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Use caution in the placement, maintenance, and removal of vascular access sheath; avoid femoral <i>vein</i> sheath placement.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; When inserting sheath, puncture only anterior wall of femoral artery; avoid Seldinger (through and through) technique.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Observe appropriate precautions while sheath is in place (e.g., complete bed rest, elevation of head ≤30°, restrain limb in which sheath is inserted, frequent monitoring of vascular access site and distal pulse in the involved limb).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Following PCI, discontinue heparin immediately; remove arterial sheath within 6 hours following PCI (at least 2 hours after discontinuation of heparin) if aPTT ≤50 seconds or ACT ≤175 seconds.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Following sheath removal, apply pressure to femoral artery for at least 30 minutes to achieve hemostasis.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Measure and monitor hematomas for enlargement.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>To avoid vascular and other trauma, minimize arterial or venous punctures, IM injections, cutdown sites, and use of nasotracheal intubation, nasogastric tubes, urinary catheters, and automatic BP cuffs; avoid establishment of IV access at noncompressible sites (e.g., subclavian or jugular veins); consider using an indwelling venipuncture device (e.g., heparin lock) for drawing blood; document and monitor vascular puncture sites; and remove dressings gently and carefully.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>If emergency surgery is needed, discontinue abciximab.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Risk of thrombocytopenia.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Severe thrombocytopenia (platelet count &lt;20,000/mm<sup>3</sup>)&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;19&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;46&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;66&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; reported more frequently than with tirofiban.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;32&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;54&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;67&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;68&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Determine platelet count prior to treatment, at 2–4 hours following initial IV injection, and at 24 hours following initiation of therapy or prior to discharge, whichever occurs first.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;9&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Consider possibility of pseudothrombocytopenia or heparin-induced thrombocytopenia (in patients receiving concomitant heparin therapy).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;14&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;47&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;54&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;59&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;70&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Exclude pseudothrombocytopenia caused by an in vitro anticoagulant interaction by sampling blood in tubes containing edetate disodium (EDTA), citrate, or heparin.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; A low platelet count in the presence of EDTA but not in the presence of heparin and/or citrate supports of a diagnosis of pseudothrombocytopenia.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>If true thrombocytopenia is verified, discontinue abciximab and initiate appropriate treatment and monitoring.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Platelet transfusions may partially restore platelet function.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Possible increased incidence and severity of thrombocytopenia following readministration.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Contraindicated in patients with platelet counts &lt;100,000/mm<sup>3</sup>.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Prior to administration, obtain platelet count, PT, ACT, and aPTT.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Monitor platelet count during and after treatment.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Thrombocytopenia under Cautions.)</p><p>When abciximab is initiated 18–24 hours prior to PCI, maintain aPTT between 60–85 seconds.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; During PCI, maintain ACT ≥200 seconds.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;10&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;12&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;16&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;19&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;45&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;46&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;77&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; If anticoagulation is continued following PCI, maintain aPTT between 55–75 seconds.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Monitor aPTT or ACT prior to arterial sheath removal; do not remove sheath unless aPTT ≤50 seconds or ACT is 150–180 seconds (approximately 6 hours after PCI).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Category C.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Not known whether abciximab is distributed into milk.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Use with caution.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;9&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Safety and efficacy not established in children &lt;18 years of age.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;9&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>No substantial differences in safety and efficacy in patients 65–74 years of age relative to younger adults.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Insufficient experience in patients ≥75 years of age to determine whether these patients respond differently than younger adults.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Common Adverse Effects</h3><p>Bleeding, back pain, hypotension, nausea, chest pain, vomiting, headache, bradycardia, puncture site pain, abdominal pain, peripheral edema.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2 class="ddc-anchor-offset" id="interactions">Interactions for Abciximab</h2><p>No formal drug interaction studies to date.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Specific Drugs</h3><p>Drug</p><p>Interaction</p><p>Comments</p><p>Anticoagulants, oral</p><p>Potential increased risk of bleeding&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Use with caution&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Dextran</p><p>Increased risk of bleeding&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Concomitant use contraindicated&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Dipyridamole</p><p>Potential increased risk of bleeding&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Use with caution&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Heparin</p><p>Increased risk of bleeding&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Monitor aPTT or ACT during therapy&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>NSAIAs</p><p>Potential increased risk of bleeding&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Use with caution&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Thrombolytics (e.g., reteplase)</p><p>Increased risk of major bleeding&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Weigh risk against anticipated benefit of concomitant therapy&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Ticlopidine</p><p>Potential increased risk of bleeding&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Use with caution&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2 class="ddc-anchor-offset" id="pharmacokinetics">Abciximab Pharmacokinetics</h2><h3>Absorption</h3><p>Maximal inhibition of platelet aggregation occurs within 10 minutes following IV administration.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Bleeding time returns to ≤12 minutes within 12–24 hours following discontinuance of infusion.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Platelet function generally recovers within 48 hours.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Distribution</h3><p>Not known whether abciximab is distributed into breast milk or is absorbed systemically after ingestion.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Elimination</h3><p>Initial half-life is &lt;10 minutes; second phase half-life is about 30 minutes.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Abciximab remains in circulation for ≥15 days in a platelet-bound state.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2>Stability</h2><h3>Storage</h3><p>2–8°C.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Do not freeze.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Compatibility</h3><p>For information on systemic interactions resulting from concomitant use, see Interactions.</p><p>No incompatibilities observed with glass bottles, PVC bags, or IV administration sets.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>No incompatibilities observed with IV fluids.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Compatible</p><p>Dextrose 5%</p><p>Sodium chloride 0.9%</p><p>No incompatibilities observed with commonly used cardiovascular drugs.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Nevertheless, administer abciximab in separate IV line whenever possible; do not mix with other drugs.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Compatible</p><p>Adenosine&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Atropine sulfate&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Bivalirudin</p><p>Diphenhydramine HCl&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Fentanyl citrate&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Metoprolol tartrate&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Midazolam HCl&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2>Actions</h2><ul>
<li>
<p>Fab fragment of chimeric human-murine monoclonal immunoglobulin antibody 7E3.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;5&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;6&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Binds selectively to platelet GP IIb/IIIa receptors and reversibly inhibits platelet aggregation (by preventing binding of fibrinogen, von Willebrand factor, and other adhesive ligands to GP IIb/IIIa receptors).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;5&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
</ul><p>Fab fragment of chimeric human-murine monoclonal immunoglobulin antibody 7E3.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;5&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;6&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Binds selectively to platelet GP IIb/IIIa receptors and reversibly inhibits platelet aggregation (by preventing binding of fibrinogen, von Willebrand factor, and other adhesive ligands to GP IIb/IIIa receptors).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;5&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2 class="ddc-anchor-offset" id="patient-advice">Advice to Patients</h2><ul>
<li>
<p>Risk of serious bleeding or hemorrhage.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;5&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;9&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Importance of close laboratory monitoring.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Importance of informing clinicians of existing or contemplated therapy, including prescription and OTC drugs and dietary or herbal supplements, as well as any concomitant illnesses (e.g., cardiovascular disease).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Importance of advising patients of other important precautionary information.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Cautions.)</p>
</li>
</ul><p>Risk of serious bleeding or hemorrhage.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;5&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;9&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Importance of close laboratory monitoring.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Importance of informing clinicians of existing or contemplated therapy, including prescription and OTC drugs and dietary or herbal supplements, as well as any concomitant illnesses (e.g., cardiovascular disease).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Importance of advising patients of other important precautionary information.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Cautions.)</p><h2 class="ddc-anchor-offset" id="preparations">Preparations</h2><p><i>Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.</i></p><p><i>Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.</i></p><p>Routes</p><p>Dosage Forms</p><p>Strengths</p><p>Brand Names</p><p>Manufacturer</p><p>Parenteral</p><p>Injection, for IV use</p><p>2 mg/mL (10 mg)</p><p>ReoPro<sup></sup></p><p>Lilly</p><p>AHFS<sup></sup> DI Essentials™. © Copyright 2021, Selected Revisions September 18, 2017. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814.</p><p>† Use is not currently included in the labeling approved by the US Food and Drug Administration.</p><h2>References</h2><p>1. Eli Lilly and Company. ReoPro<sup></sup> (abciximab) injection for intravenous administration prescribing information. Indianapolis, IN; 2005 Jun. 3.</p><p>2. Topol EJ, Califf RM, Weisman HF et al. Randomized trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. <i>Lancet</i>. 1994; 343:881-5. http://www.ncbi.nlm.nih.gov/pubmed/7908357?dopt=AbstractPlus</p><p>3. Simoons ML, de Boer MJ, van den Brand MJ et al. Randomized trial of GpIIb/IIIa platelet receptor blocker in refractory unstable angina. <i>Circulation</i>. 1994; 89:596-603. http://www.ncbi.nlm.nih.gov/pubmed/7508826?dopt=AbstractPlus</p><p>4. EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. <i>N Engl J Med</i>. 1994; 330: 956-61.</p><p>5. Anon. Centocor will begin shipping Reopro to Lilly in early January: Reopro is the first GpIIbIIIa antagonist for PTCA patients at high risk for ischemic complications. <i>F-D-C Rep</i>. 1995 Jan:16-7.</p><p>6. Tcheng JE, Ellis SG, George BS et al. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty. <i>Circulation</i>. 1994; 90:1757-64. http://www.ncbi.nlm.nih.gov/pubmed/7923659?dopt=AbstractPlus</p><p>7. Eli Lilly and Company, Indianapolis, IN: Personal communication.</p><p>8. Ellis SG, Tcheng JE, Navetta FI et al. Safety and antiplatelet effect of murine monoclonal antibody 7E3Fab directed against platelet glycoprotein IIb/IIIa in patients undergoing elective coronary angioplasty. <i>Cor Art Dis</i>. 1993; 4:167-75.</p><p>9. Eli Lilly and Company, Indianapolis, IN: Personal communication.</p><p>10. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. <i>N Engl J Med</i>. 1997; 336:1689-96. http://www.ncbi.nlm.nih.gov/pubmed/9182212?dopt=AbstractPlus</p><p>11. The CAPTURE Investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. <i>Lancet</i>. 1997; 349:1429-35. http://www.ncbi.nlm.nih.gov/pubmed/9164316?dopt=AbstractPlus</p><p>12. Kleiman NS. A risk-benefit assessment of abciximab in angioplasty. <i>Drug Saf</i>. 1999; 20:43-57. http://www.ncbi.nlm.nih.gov/pubmed/9935276?dopt=AbstractPlus</p><p>13. Detre KM, Holmes DR Jr, Holubkov R et al. Incidence and consequences of periprocedural occlusion: the 1985–1986 National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry. <i>Circulation</i>. 1990; 82:739-50. http://www.ncbi.nlm.nih.gov/pubmed/2394000?dopt=AbstractPlus</p><p>14. Lincoff AM. Trials of platelet glycoprotein IIb/IIIa receptor antagonists during percutaneous coronary revascularization. <i>Am J Cardiol</i>. 1998; 82:36P-42P. http://www.ncbi.nlm.nih.gov/pubmed/9809890?dopt=AbstractPlus</p><p>15. Alexander JH, Harrington RA. Recent antiplatelet drug trials in the acute coronary syndromes. Clinical interpretation of PRISM, PRISM-PLUS, PARAGON A, and PURSUIT. <i>Drugs</i>. 1998; 56:965-76. http://www.ncbi.nlm.nih.gov/pubmed/9878986?dopt=AbstractPlus</p><p>16. White H. Unmet therapeutic needs in the management of acute ischemia. <i>Am J Cardiol</i>. 1997; 80(Suppl 4A):2b-10b. http://www.ncbi.nlm.nih.gov/pubmed/9291240?dopt=AbstractPlus</p><p>17. Tcheng JE. Glycoprotein IIb/IIIa receptor inhibitors: putting the EPIC, IMPACT II, RESTORE, and EPILOG trials into perspective. <i>Am J Cardiol</i>. 1996; 78(Suppl 3A):35-40. http://www.ncbi.nlm.nih.gov/pubmed/8751845?dopt=AbstractPlus</p><p>19. Reviewers’ comments (personal observations) on eptifibatide.</p><p>20. Sebastian M, Makkar R. Glycoprotein IIb/IIIa receptor antagonists: clinical pharmacology in cardiovascular diseases of aging. <i>Drugs &amp; Aging</i>. 1999; 15:207-18.</p><p>21. Foster RH, Wiseman LR. Abciximab: an updated review of its use in ischaemic heart disease. <i>Drugs</i>. 1998; 56:629-65. http://www.ncbi.nlm.nih.gov/pubmed/9806109?dopt=AbstractPlus</p><p>22. Anon. Randomised placebo-controlled trial of effect of eptifibatide on complication of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II. <i>Lancet</i>. 1997; 349:1422-8. http://www.ncbi.nlm.nih.gov/pubmed/9164315?dopt=AbstractPlus</p><p>23. Tcheng JE. Impact of eptifibatide on early ischemic events in acute ischemic coronary syndromes: a review of the IMPACT II trial. <i>Am J Cardiol</i>. 1997; 80(Suppl 4A):21B-8B. http://www.ncbi.nlm.nih.gov/pubmed/9291242?dopt=AbstractPlus</p><p>25. Agency for Health Care Policy and Research. Diagnosing and managing unstable angina. 1994. (AHCPR publication no. 94-0603)</p><p>27. Antiplatelet Trialists’ Collaboration. Collaborative overview of randomised trials of antiplatelet therapy—I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. <i>BMJ</i>. 1994; 308:81-106. http://www.ncbi.nlm.nih.gov/pubmed/8298418?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&amp;artid=2539220&amp;blobtype=pdf</p><p>28. Cairns JA, Gent M, Singer J et al. Aspirin, sulfinpyrazone, or both in unstable angina: results of a Canadian multicenter trial. <i>N Engl J Med</i>. 1985; 313:1369-75. http://www.ncbi.nlm.nih.gov/pubmed/3903504?dopt=AbstractPlus</p><p>29. Lewis HD, Davies JW, Archibald DG et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study. <i>N Engl J Med</i>. 1983; 309:396-403. http://www.ncbi.nlm.nih.gov/pubmed/6135989?dopt=AbstractPlus</p><p>30. The RISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. <i>Lancet</i>. 1990; 336:827-30. http://www.ncbi.nlm.nih.gov/pubmed/1976875?dopt=AbstractPlus</p><p>31. Théroux P, Waters D, Qiu S et al. Aspirin versus heparin to prevent myocardial infarction during the acute phase of unstable angina. <i>Circulation</i>. 1993; 88(5 Pt 1):2045-8. http://www.ncbi.nlm.nih.gov/pubmed/8222097?dopt=AbstractPlus</p><p>32. Théroux P, Ouimet H, McCans J et al. Aspirin, heparin, or both to treat acute unstable angina. <i>N Engl J Med</i>. 1988; 319:1105-11. http://www.ncbi.nlm.nih.gov/pubmed/3050522?dopt=AbstractPlus</p><p>33. Théroux P, Fuster V. Acute coronary syndromes: unstable angina and non-Q-wave myocardial infarction. <i>Circulation</i>. 1998; 97:1195-1206. http://www.ncbi.nlm.nih.gov/pubmed/9537346?dopt=AbstractPlus</p><p>34. Tonkin AM, Aroney CN. Guidelines for managing patients with unstable angina: rating the evidence and rationale for treatment. <i>Med J Aust</i>. 1997; 16:644-7.</p><p>35. Cohen M, Demers C, Gurfinkel EP et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. <i>N Engl J Med</i>. 1997; 337: 447-52. http://www.ncbi.nlm.nih.gov/pubmed/9250846?dopt=AbstractPlus</p><p>36. Armstrong PW. Heparin in acute coronary disease-requiem for a heavyweight? <i>N Engl J Med</i>. 1997; 337:492-4. (IDIS 389821)</p><p>37. Swahn E, Wallentin L for the FRISC study group. Low-molecular weight heparin (fragmin) during instability in coronary artery disease (FRISC). <i>Am J Cardiol</i>. 1997; 80(Suppl. 5A):25E-9E. http://www.ncbi.nlm.nih.gov/pubmed/9296466?dopt=AbstractPlus</p><p>38. Scarborough RM, Kleiman NS, Phillips DR. Platelet glycoprotein IIb/IIIa antagonists: what are the relevant issues concerning their pharmacology and clinical use? <i>Circulation</i>. 1999; 100:437-44.</p><p>39. Théroux P. Antiplatelet therapy: do the new platelet inhibitors add significantly to the clinical benefits of aspirin? <i>Am Heart J</i>. 1997; 134:S62-70.</p><p>40. Cohen M, Adams PC, Gareth P et al. Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users: Primary end points analysis for the ATACS trial. <i>Circulation</i>. 1994; 89:81-8. http://www.ncbi.nlm.nih.gov/pubmed/8281698?dopt=AbstractPlus</p><p>41. Oler A, Whooley MA, Oler J et al. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina: a meta-analysis. <i>JAMA</i>. 1996; 276:811-5. http://www.ncbi.nlm.nih.gov/pubmed/8769591?dopt=AbstractPlus</p><p>43. Topol EJ. Targeted approaches to thrombus formation: an end to the shotgun approach. <i>Clin Cardiol</i>. 1997; 20(Suppl I):I-22-6.</p><p>44. Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. <i>N Engl J Med</i>. 1995; 332:1553-9. http://www.ncbi.nlm.nih.gov/pubmed/7739710?dopt=AbstractPlus</p><p>45. Tcheng JE, Harrington RA, Kottke-Marchant K et al. Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker Integrilin in elective coronary intervention. <i>Circulation</i>. 1995; 91:2151-7. http://www.ncbi.nlm.nih.gov/pubmed/7697843?dopt=AbstractPlus</p><p>46. Cor Therapeutics, South San Francisco, CA, and Key Pharmaceuticals, Kenilworth, NJ: Personal communication on eptifibatide.</p><p>47. Madan M, Berkowitz SD, Tcheng JE. Glycoprotein IIb/IIIa integrin blockade. <i>Circulation</i>. 1998; 98:2629-35. http://www.ncbi.nlm.nih.gov/pubmed/9843473?dopt=AbstractPlus</p><p>48. The RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. <i>Circulation</i>. 1997; 96:1445-53. http://www.ncbi.nlm.nih.gov/pubmed/9315530?dopt=AbstractPlus</p><p>49. Adgey AAJ. An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors. <i>Am Heart J</i>. 1998; 135:S43-55.</p><p>50. Dobesh PP, Latham KA. Advancing the battle against ischemic syndromes: a focus on the GP-IIb/IIIa inhibitors. <i>Pharmacotherapy</i>. 1998; 18:663-85. http://www.ncbi.nlm.nih.gov/pubmed/9692642?dopt=AbstractPlus</p><p>51. Kong DF, Califf Rm, Miller DP et al. Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ishemic heart disease. <i>Circulation</i>. 1998; 98:2829-35. http://www.ncbi.nlm.nih.gov/pubmed/9860783?dopt=AbstractPlus</p><p>52. Vorchheimer DA, Badimon JJ, Fuster V. Platelet glycoprotein IIb/IIIa receptor antagonists in cardiovascular disease. <i>JAMA</i>. 1999; 281:1407-14. http://www.ncbi.nlm.nih.gov/pubmed/10217057?dopt=AbstractPlus</p><p>53. Giugliano RP, Hyatt RR. Thrombocytopenia with GP IIb/IIIa inhibitors: a meta-analysis. <i>J Am Coll Cardiol</i>. 1998; 31(Suppl 2A):185A.</p><p>54. Ferguson JJ, Kereiakes DJ, Adgey AAJ et al. Safe use of platelet GP IIb/IIIa inhibitors. <i>Am Heart J</i>. 1998; 135:S77-89.</p><p>55. Quinn M, Fitzgerald DJ. Long-term administration of glycoprotein IIb/IIIa antagonists. <i>Am Heart J</i>. 1998; 135:S113-8. http://www.ncbi.nlm.nih.gov/pubmed/9588390?dopt=AbstractPlus</p><p>56. Topol EJ, Byzova TV, Plow EF. Platelet GPIIb/IIIa blockers. <i>Lancet</i>. 1999; 353:227-31. http://www.ncbi.nlm.nih.gov/pubmed/9923894?dopt=AbstractPlus</p><p>57. Key Pharmaceuticals. Integrelin™ (eptifibatide) injection prescribing information. Kenilworth, NJ; 1998 May.</p><p>59. Merck &amp; Co. Aggrastat<sup></sup> (tirofiban hydrochloride) injection premixed and injection prescribing information. West Point, PA; 1999 Jul.</p><p>60. Reviewers’ comments (personal observations) on tirofiban.</p><p>61. Merck &amp; Co., West Point, PA: Personal communication on tirofiban.</p><p>62. Peerlinck, De Lepeleire I, Goldberg M et al. MK-383 (L-700,462), a selective nonpeptide platelet glycoprotein IIb/IIIa antagonist, is active in man. <i>Circulation</i>. 1993; 88:1512-7. http://www.ncbi.nlm.nih.gov/pubmed/8403299?dopt=AbstractPlus</p><p>63. Phillips DR, Scarborough RM. Clinical pharmacology of eptifibatide. <i>Am J Cardiol</i>. 1997; 80(Suppl 4A):11b-20b. http://www.ncbi.nlm.nih.gov/pubmed/9291241?dopt=AbstractPlus</p><p>64. Key Pharmaceuticals. Integrilin™ (eptifibatide) product monograph. Kenilworth, NJ; 1998 Aug.</p><p>65. Le Breton H, Plow EF, Topol EJ et al. Role of platelets in restenosis after percutaneous coronary revascularization. <i>J Am Coll Cardiol</i>. 1996; 28:1643-51. http://www.ncbi.nlm.nih.gov/pubmed/8962547?dopt=AbstractPlus</p><p>66. PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. <i>N Engl J Med</i>. 1998; 339:436-43. http://www.ncbi.nlm.nih.gov/pubmed/9705684?dopt=AbstractPlus</p><p>67. Kereiakes DJ, Kleiman NS, Ambrose J et al. Randomized, double-blind, placebo-controlled dose-ranging study of tirofiban (MK-383) platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplasty. <i>J Am Coll Cardiol</i>. 1996; 27:536-42. http://www.ncbi.nlm.nih.gov/pubmed/8606262?dopt=AbstractPlus</p><p>68. Ferguson JJ, Waly HM, Wilson JM. Fundamentals of coagulation and glycoprotein IIb/IIIa receptor inhibition. <i>Am Heart J</i>. 1998; 135:S35-42. http://www.ncbi.nlm.nih.gov/pubmed/9539494?dopt=AbstractPlus</p><p>69. Harrington RA. Design and methodology of the PURSUIT trial: evaluating eptifibatide for acute coronary syndromes. <i>Am J Cardiol</i>. 1997; 80(Suppl 4A):34b-8b. http://www.ncbi.nlm.nih.gov/pubmed/9291244?dopt=AbstractPlus</p><p>70. Merck &amp; Co. Product information form for American hospital formulary service: Aggrastat<sup></sup> (tirofiban hydrochloride). West Point, PA; 1998.</p><p>72. Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. <i>N Engl J Med</i>. 1995; 332:1553-9. http://www.ncbi.nlm.nih.gov/pubmed/7739710?dopt=AbstractPlus</p><p>73. Topol EJ, Ferguson JJ, Weisman HF et al. Long-term protection from myocardial ischemic events in a randomized trial of brief integrin β<sub>3</sub> blockade with percutaneous coronary intervention. <i>JAMA</i>. 1997; 278:479-84. http://www.ncbi.nlm.nih.gov/pubmed/9256222?dopt=AbstractPlus</p><p>74. Lincoff AM, Tcheng JE, Califf RM et al. Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one year outcome in the EPILOG trial. <i>Circ</i>. 1999; 99:1951-8.</p><p>75. Ghaffari S, kereiakes DJ, Lincoff AM et al. Platelet glycoprotein IIb/IIIa receptor blockade with abciximab reduces ischemic complications in patients undergoing directional atherectomy. <i>Am J Cardiol</i>. 1998; 82:7-12. http://www.ncbi.nlm.nih.gov/pubmed/9671000?dopt=AbstractPlus</p><p>76. Keriakes D, Lincoff AM, Miller DP et al. Abciximab therapy and unplanned coronary stent deployment: favorable effects on stent use, clinical outcomes, and bleeding complications. <i>Circ</i>. 1998; 97:857-64.</p><p>77. The EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. <i>Lancet</i>. 1998; 352:87-92. http://www.ncbi.nlm.nih.gov/pubmed/9672272?dopt=AbstractPlus</p><p>78. Lincoff AM, Califf RM, Moliterno DJ et al. Complementary clinical benefits of coronary-artery stenting and blockade of platelet gycoprotein IIb/IIIa receptors. <i>N Engl J Med</i>. 1999; 341:319-27. http://www.ncbi.nlm.nih.gov/pubmed/10423466?dopt=AbstractPlus</p><p>79. Steinhubl SR, Wolski K, Lincoff AM et al. Ticlopidine pretreatment before coronary stenting is associated with sustained decrease in adverse cardiac events: data from the Evaluation of Platelet IIb/IIIa Inhibitor for Stenting (EPISTENT) trial. <i>Circulation</i>. 2001; 103:1403-9. http://www.ncbi.nlm.nih.gov/pubmed/11245644?dopt=AbstractPlus</p><p>80. Topol EJ, Lincoff AM, Cohen E et al. Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results for a multicentre randomised trial. <i>Lancet</i>. 1999; 354:2019-24. http://www.ncbi.nlm.nih.gov/pubmed/10636365?dopt=AbstractPlus</p><p>81. Eli Lilly and Company. ReoPro<sup></sup> (abciximab) injection for intravenous administration prescribing information. Indianapolis, IN; 1998 Feb 12.</p><p>82. Akkerhuis KM, Deckers JW, Lincoff AM et al. Risk of stroke associated with abciximab among patients undergoing percutaneous coronary intervention. <i>JAMA</i>. 2001; 286:78-82. http://www.ncbi.nlm.nih.gov/pubmed/11434830?dopt=AbstractPlus</p><p>87. Brener SJ, Barr LA, Burchenal JE et al. Randomized, placebo-controlled trial of platelet glycoprotein I blockade with primary angioplasty for acute myocardial infarction. <i>Circulation</i>. 1998; 98:734-41. http://www.ncbi.nlm.nih.gov/pubmed/9727542?dopt=AbstractPlus</p><p>88. Neumann FJ, Kastrati A, Schmitt C et al. Effect of glycoprotein IIb/IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after placement of coronary stents following acute myocardial infarction. <i>J Am Coll Cardiol</i>. 2000; 35: 915-21. http://www.ncbi.nlm.nih.gov/pubmed/10732888?dopt=AbstractPlus</p><p>89. Simoons ML and GUSTO IV-ACS investigators. Effect of glycoprotein IIb/IIIa recptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularization: the GUSTO IV-ACS randomised trial. <i>Lancet</i>. 2001; 357:1915-24. http://www.ncbi.nlm.nih.gov/pubmed/11425411?dopt=AbstractPlus</p><p>90. Cohen M. Glycoprotein IIb/IIIa receptor blockers in acute coronary syndromes: GUSTO IV-ACS. <i>Lancet</i>. 2001; 357:1899-900. http://www.ncbi.nlm.nih.gov/pubmed/11425405?dopt=AbstractPlus</p><p>91. Antman EM, Fox KM for the International Cardiology Forum. Guidelines for the diagnosis and management of unstable angina and non-Q-wave myocardial infarction: proposed revisions. <i>Am Heart J</i>. 2000; 139:461-75. http://www.ncbi.nlm.nih.gov/pubmed/10689261?dopt=AbstractPlus</p><p>92. Cairns J, Théroux P, Armstrong P et al. Unstable angina—Report from a Canadian expert round table. <i>Can J Cardiol</i>. 1996; 12:1279-92. http://www.ncbi.nlm.nih.gov/pubmed/8987969?dopt=AbstractPlus</p><p>93. Armstrong PW. Pursuing progress in acute coronary syndromes. <i>Circulation</i>. 1999; 100:1586-9. http://www.ncbi.nlm.nih.gov/pubmed/10517727?dopt=AbstractPlus</p><p>94. Kaul S, Shah PK. Low molecular weight heparin in acute coronary syndrome: evidence for superior or equivalent efficacy compared with unfractionated heparin? <i>J Am Coll Cardiol</i>. 2000; 35:1699-702.</p><p>99. Goodman S. Enoxaparin and glycoprotein IIb/IIIa inhibition in non-ST-segement-elevation acute coronary syndrome: insights for the INTERACT trial. <i>Am Heart J</i>. 2005; 149:S73-80. http://www.ncbi.nlm.nih.gov/pubmed/16124951?dopt=AbstractPlus</p><p>100. James S, Armstrong P, Califf R et al. Safety and efficacy of abciximab combined with dalteparin in the treatment of acute coronary syndromes. <i>Eur Heart J</i>. 2002; 23:1538-45. http://www.ncbi.nlm.nih.gov/pubmed/12242074?dopt=AbstractPlus</p><p>101. Goodman SG, Fitchett D, Armstrong P et al. Randomized evaluation of the safety and efficacy of enoxaparin versus unfarctionated heparin in high-risk patients with non-ST-sgement elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. <i>Circulation</i>. 2003; 107:238-44. http://www.ncbi.nlm.nih.gov/pubmed/12538422?dopt=AbstractPlus</p><p>103. Lansky AJ, Hochman JS, Ward PA et al. Percutaneous coronary intervention and adjunctive pharmacotherapy in women: a statement for healthcare professional from the American Heart Association. <i>Circulation</i>. 2005; 111:940-3. http://www.ncbi.nlm.nih.gov/pubmed/15687113?dopt=AbstractPlus</p><p>104. Kastrati A, Mehilli J, Neumann FJ et al. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomzed trial. <i>JAMA</i>. 2006; 295:1531-8. http://www.ncbi.nlm.nih.gov/pubmed/16533938?dopt=AbstractPlus</p><p>105. Moliterno DJ, Yabubov SJ, DiBattiste PM et al. Outcomes at 6 months for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularization with stent placement: the TARGET follow-up study. <i>Lancet</i>. 2002; 360:355-60. http://www.ncbi.nlm.nih.gov/pubmed/12241774?dopt=AbstractPlus</p><p>106. Eagle KA, Guyton RA, Davidoff R et al. ACC/AHA 2004 guideline update for coronary artery bypass graft surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for Coronary Artery Bypass Graft Surgery). Available at: http://content.onlinejacc.org/data/Journals/JAC/23023/08002.pdf. Accessed 2006 Nov 10.</p><p>111. Baroletti S, Hartman C, Churchill W. Visual compatibility of abciximab with selected drugs. Am J Health-Sys Pharm 2002; 59:466-7.</p><p>991. Anderson JL, Adams CD, Antman EM et al. 2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i>. 2011; 123:e426-579.</p><p>994. Levine GN, Bates ER, Blankenship JC et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. <i>J Am Coll Cardiol</i>. 2011; 58:e44-122. http://www.ncbi.nlm.nih.gov/pubmed/22070834?dopt=AbstractPlus</p><p>995. Hamm CW, Bassand JP, Agewall S et al, for The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST -segment elevation of the European Society of Cardiology (ESC). ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. <i>Eur Heart J</i>. 2011; 32:2999-3054. http://www.ncbi.nlm.nih.gov/pubmed/21873419?dopt=AbstractPlus</p><p>1016. Eikelboom JW, Hirsh J, Spencer FA et al. Antiplatelet drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. <i>Chest</i>. 2012; 141(2 Suppl):e89S-119S.</p><p>1100. Amsterdam EA, Wenger NK, Brindis RG et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i>. 2014; 130:e344-426. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&amp;artid=4676081&amp;blobtype=pdf</p><p>HID. Trissel LA. Handbook on injectable drugs. 13th ed; Bethesda, MD: American Society of Health-System Pharmacists; 2005:3.</p><h2>More about abciximab</h2><ul class="more-resources-list more-resources-list-general">
<li>Side Effects</li>
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Drug class: glycoprotein platelet inhibitors</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Advanced Reading</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>High Risk Percutaneous Transluminal Angioplasty</li>
</ul><p class="ddc-disclaimer-link">Medical Disclaimer</p></body></html>